4,4`-(Α,4-二氯亚苄基)双[2,2`-(苯胺)二乙醇] | 143218-70-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: 4,4`-(Α,4-二氯亚苄基)双[2,2`-(苯胺)二乙醇]
• 英文名称: 2-[4-[[4-[bis(2-hydroxyethyl)amino]phenyl]-chloro-(4-chlorophenyl)methyl]-N-(2-hydroxyethyl)anilino]ethanol
• CAS: 143218-70-6
• 化学式: C₂₇H₃₂Cl₂N₂O₄
• 分子量: 519.5
• InChiKey: AUXWTORBMDGIMZ-UHFFFAOYSA-N

物化性质

• 熔点：
  150 °C (dec.)(lit.)
• 沸点：
  739.4±60.0 °C(Predicted)
• 密度：
  1.338±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  35
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  87.4
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• WGK Germany：
  3

文献信息

• [EN] NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS<br/>[FR] MIMÉTIQUES NON PEPTIDIQUES DE NEUROTROPHINE BDNF
  申请人：PHARMATROPHIX INC

  公开号：WO2014144342A1

  公开（公告）日：2014-09-18

  Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule, optionally optionally in combination with a TrkA and/or TrkC receptor molecule.

  提供用于治疗神经和其他疾病的方法和化合物。其中包括向需要治疗的受试者施用具有与TrkB受体分子结合和/或调节特异性的化合物的有效量，可选地与TrkA和/或TrkC受体分子结合。
• NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS
  申请人：PHARMATROPHIX, INC.

  公开号：US20160046559A1

  公开（公告）日：2016-02-18

  Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule, optionally optionally in combination with a TrkA and/or TrkC receptor molecule.

  提供用于治疗神经和其他疾病的方法和化合物。其中包括向需要治疗的对象施用具有与TrkB受体分子结合和/或调节特异性的化合物的有效量，可选地与TrkA和/或TrkC受体分子结合使用。
• Methods Of Inhibiting Osteoclast Activity
  申请人：Greene Mark I.

  公开号：US20090306030A1

  公开（公告）日：2009-12-10

  Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. According to the methods, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Pharmaceutical compositions which comprise TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of a TRANCE/RANK inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.
• US7566741B2
  申请人：——

  公开号：US7566741B2

  公开（公告）日：2009-07-28
• US8003628B2
  申请人：——

  公开号：US8003628B2

  公开（公告）日：2011-08-23